Almost fifty years after its first introduction into clinical care, clozapine remains the only
evidence-based pharmacological option for treatment-resistant schizophrenia (TRS), which …

Genetic factors contribute to the phenotype of drug response. We systematically analyzed all
available pharmacogenetic data from Medline databases (1970–2003) on the impact that …

Up to 30% of people with schizophrenia do not respond to two (or more) trials of
dopaminergic antipsychotics. They are said to have treatment-resistant schizophrenia (TRS) …

Importance of the field: Antipsychotic drug is the mainstay of treatment for schizophrenia,
and there are large inter-individual differences in clinical response and side effects …

Schizophrenia is a common debilitating disease characterized by continuous or relapsing
episodes of psychosis. Although the molecular mechanisms underlying this psychiatric …

There are two families of dopamine (DA) receptors, called D1 and D2, respectively. The D1
family consists of D1-and D5-receptor subtypes and the D2 family consists of D2-, D3-, and …

Many genetic studies have focussed on dopamine receptors and their relationship to
neuropsychiatric disease. Schizophrenia, bipolar disorder, and substance abuse have been …

Typically reported as vivid, multisensory experiences which may spontaneously resolve,
hallucinations are present at high rates during childhood. The risk of associated …

Although the molecular mechanisms underlying psychiatric illnesses such as depression,
bipolar disorder and schizophrenia remain incompletely understood, there is increasing …

We have been studying the pharmacogenetic correlates of side effects and early response
to antipsychotic treatment in a series of Chinese Han first-episode drug-naïve patients with …